CD22 and neoplasm: In an encouraging outcome published by Shalabi et al., prescribing blinatumomab alongside anti-CD22, CAR-T cell therapy led to the complete eradication of tumor cells and the prolonged life span of patients who relapsed after anti-CD22 CAR-T cell monotherapy.